PeptidePedia The community reference

Talk:SURPASS trial programme

Discussion page·2 threads·no archives

This article is within the scope of the clinical evidence working group.

This is the discussion page for the article SURPASS trial programme. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Cross-trial comparison of SURMOUNT and STEPResolved

People treat SURMOUNT-1 versus STEP 1 as a head-to-head. It is not, and this article is a sensible place to say why since readers arrive here looking for the comparison. — SurpassSunniva (talk) 09:50, 26 January 2026 (UTC)

Listed the specific differences — population, duration, escalation, lifestyle arm — rather than only asserting incomparability. ✓ Done — ForestPlotFinn (talk) 13:25, 26 January 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Active-comparator CVOTDone

Non-inferiority to an agent with demonstrated benefit is a stronger claim than non-inferiority to placebo, and that distinction is worth spelling out. — SelectTrialSam (talk) 10:30, 16 April 2026 (UTC)

Added to the table note. It is the main reason SURPASS-CVOT is designed the way it is. ✓ Done — EndpointEnid (talk) 14:05, 16 April 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 16 April 2026, by EndpointEnid. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).